PLANTOGRAM · DOCTORS’ EDUCATION
Medicinal Cannabis in Australia: Access and Product Formats
Explore Australian medicinal cannabis access, oral and inhaled product formats, clinical selection factors and the limits of market statistics.
An overview of the Australian landscape
Australia’s medicinal cannabis landscape includes registered medicines and products accessed through unapproved-medicine pathways. For doctors, understanding this distinction matters more than the size of a product catalogue.
This overview explains access and product formats. The companion market-growth resource explains how to interpret approval and patient statistics.
Registered and unapproved medicines
Inclusion in the Australian Register of Therapeutic Goods and permission to access an unapproved medicine are different regulatory concepts. A listing in an access-scheme product resource should not be described as registration or evidence that the TGA has evaluated the product’s efficacy.
The TGA’s current supplied-product list can help with category matching. Its reporting period and limitations should be checked, and listing does not guarantee present availability.
| Format group | What to assess | Avoid assuming |
|---|---|---|
| Oral oils and liquids | Concentration, measured volume, food effects and administration method. | All oils act quickly or provide the same duration. |
| Capsules, softgels, gummies and other oral units | Fixed-unit content, swallowing, excipients and suitability for dose adjustment. | All units can be divided accurately or have identical absorption. |
| Oromucosal sprays | Product-specific instructions, delivered amount and technique. | An effect or onset applies to every spray formulation. |
| Inhaled flower and cartridges | Device, actual administration, exposure and route-specific risks. | A short onset guarantees precise dosing or makes the route appropriate for acute anxiety. |
| Topical and transdermal products | Whether intended action is local or systemic, and product-specific evidence. | All creams act only locally or every patch has validated systemic delivery. |
| Powders, emulsions and other delivery systems | Preparation, stability, exposure and evidence for the actual technology. | A “nano” or emulsion label proves improved clinical outcomes. |
Onset and duration require product context
The product, dose, food, device, route and individual response can alter the timing and intensity of effects.
When counselling a patient, use information applicable to the actual prescribed preparation. Explain uncertainty and the risk of repeating a dose before its effect can be judged.
Does every patient need combined formats?
No. Daily-foundation plus breakthrough treatment, day and night regimens, and systemic plus local approaches are possible planning concepts, rather than a standard package.
Each component needs a separate reason for use. Adding products can increase complexity, cost, interactions and cumulative exposure. A clear treatment goal and review of the simplest appropriate regimen are more useful than automatically combining formats.
How costs and access should be discussed
Consultation fees, medicine costs and subsidy eligibility vary. Give patients a current written estimate where possible, distinguish consultations from dispensing and delivery, and check any subsidy against the specific medicine and patient criteria. A universal price range or statement that all products lack subsidy would be misleading.
Market share and popularity are also separate from clinical suitability. Format selection belongs within individual assessment rather than being inferred from a sales or approvals chart.
References and further reading
- TGA: Medicinal cannabis product list, updated 17 September 2026
- TGA: Applications and reporting for unapproved medicinal cannabis
- TGA: Access pathways and usage data
